Clinical Research

Genentech Reports Phase III Success For Fenebrutinib With 51 Percent Relapse Reduction In Multiple Sclerosis

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relap...

 March 03, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

 March 02, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

 March 02, 2026 | News

Gilead Reports Positive Phase 3 Data For Investigational Bictegravir And Lenacapavir Single Tablet Regimen

– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier ...

 February 27, 2026 | News

AtomVie Supplies First Patient Dose In Radiopharm Theranostics Phase 1 2a Study Of 177Lu BetaBart

AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first pat...

 February 26, 2026 | News

Antengene And Junshi Biosciences Enter Clinical Collaboration To Advance ATG 037 And JS207 Combination In Solid Tumors

Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, ...

 February 26, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

 February 25, 2026 | News

Etherna And Almirall Advance LAD116 mRNA LNP Therapy Into IND Enabling Studies For Non Melanoma Skin Cancer

 etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...

 February 25, 2026 | News

Bioxytran Initiates University Of Georgia Collaboration Under 100 Million Dollar Grant To Target H5N1 Bird Flu

Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, announced it has initiated a research c...

 February 24, 2026 | News

CStone Secures UK MHRA Approval For Sugemalimab In Stage III Non Small Cell Lung Cancer

Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...

 February 24, 2026 | News

Formosa Pharmaceuticals Signs Exclusive Licensing Agreement With Arrotex For APP13007 In Australia And New Zealand

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...

 February 24, 2026 | News

Singular Genomics Commercially Launches G4X to Scale Spatial Multiomics for Precision Medicine

 Singular Genomics, a company delivering high-throughput spatial technologies to advance precision medicine, announced the commercial launch...

 February 24, 2026 | News

AVEO Oncology Selects Ficlatuzumab Dose for Phase 3 FIERCE-HN Trial in Head and Neck Cancer

–  Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...

 February 24, 2026 | News

Deciphera Pharmaceuticals Secures FDA NDA Acceptance For Tirabrutinib In R R PCNSL

-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...

 February 20, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close